Susan received a phone call from her clinician's office recommending that she start using a pen for her insulin. She had also been prescribed a GLP-1 receptor agonist and was to go to the pharmacy to pick them up.
She went and signed up for the long 'discourse' patients receive when they pick up new meds including questions such as whether or not the pharmacist had offered instructions and pages of small print. She, like many of our patients, signed the sheets and went on her own way without ever talking to a pharmacist or asking a question.

Ricardo, a 35-year-old man, newly diagnosed with type 1 diabetes, was hospitalized for diabetic ketoacidosis (DKA).  Once he was stabilized, he wanted to go home. He refused to learn how to self-administer insulin. However, he was told he would not be discharged until he self-administered insulin, at least one time....

A new patient of mine was diagnosed with type 2 diabetes and obesity. We discussed a weight loss treatment to target both her diabetes and obesity, and she followed our mutually agreed upon treatment plan. Things were going well -- she would visit every three months and we would reassess and make treatment decision changes as needed. Then, my patient did not visit for two years. When she returned, she had gained back her weight plus a few more pounds, and her blood glucose, blood pressure and lipids were out of her target range....

A patient of mine who had diabetes and peripheral neuropathy came home from the hospital after a below-the-knee amputation of her right leg. She lived alone and was housebound. Having lost one leg, I knew she was at increased risk for losing her other leg. While in rehab, she had a professionally custom molded shoe made for her left foot which she started to wear.

Woman, 43 years of age, PCOS, prediabetes, BMI 26, B/P 130/70, A1C 5.5%, Lipids, TC-156, HDL 52, Trig 76, LDL 84, mother of 3 children, visited today. She reports that her mother had PCOS, so was very carefully watching her as a child and adolescent hoping to prevent her from developing the complications of PCOS, such as infertility, obesity, type 2 diabetes, cardiovascular disease, and/or cancer later in life.

Jeffrey Emmick MD, Ph.D is the vice president of product development at Eli Lilly and Company. Dr. Emmick has been with the organization for over 20 years in various roles. Currently, he is responsible for late-stage clinical development for the entire Lilly diabetes portfolio.

In this Exclusive Interview, Jeffrey Emmick talks with Diabetes in Control during the ADA 2018 convention about Lilly diabetes products in the pipeline.

In this Exclusive Interview, Jeffrey Emmick talks with Diabetes in Control Medical Editor Joy Pape (with a special appearance by Diabetes In Control Publisher Steve Freed) during the ADA 2018 convention in Orlando about Lilly's diabetes products in the pipeline.

In part 1 of this Exclusive Interview, Jeffrey Emmick talks with Diabetes in Control Medical Editor Joy Pape about various products Lilly has brought to market and new products in development.

In part 2 of this Exclusive Interview, Jeffrey Emmick talks with Diabetes in Control Medical Editor Joy Pape about the combination of GLP1s and SGLTs while Diabetes in Control Publisher Steve Freed makes a quick appearance to ask about the possible effects of their combined use.